

What's next for Bayer after losing \$1.56 billion Roundup glyphosate case?

Bayer AG suffered its biggest drop ever, losing about €7.6 billion (\$8.3 billion) in market value, after major legal and drug-development setbacks that raise pressure on its new leader to outline a turnaround plan.

The German pharma and agriculture company stopped the main study of its top experimental medicine due to a lack of efficacy and lost a key US trial against its weed killer Roundup.

Follow the latest news and policy debates on sustainable agriculture, biomedicine, and other 'disruptive' innovations. Subscribe to our newsletter.

[SIGN UP](#)

The announcement came two days after Bayer's Monsanto unit was [ordered](#) by a Missouri jury to pay more than \$1.5 billion to three former Roundup users who blamed their cancers on the controversial product in one of its largest trial losses over the herbicide.

Monsanto has been hit with a recent spate of jury verdicts finding Roundup contains carcinogens. The more than \$1.5 billion verdict is one of the largest damage awards handed down against a US corporate defendant this year.

Bayer said it will appeal the verdicts and insists the product is safe. Two years ago, the company set aside as much as \$16 billion to resolve more than 100,000 cases over Roundup's health impact.

[**This is an excerpt. Read the original post here**](#)